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indicate the need for additional high quality studies into patellar
taping and bracing effects on chronic knee pain.
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Purpose: Splints for base of the thumb osteoarthritis (OA) are
recommended in international guidelines but evidence for their
efﬁcacy in randomized trials are missing. The objective was to
assess the efﬁcacy and acceptability of splints for base of the
thumb OA.
Methods: Study design: Randomized controlled trial
Setting: Two tertiary care hospitals in France
Patients: 109 (94 women) patients with base of thumb car-
pometacarpal joint OA
Intervention: 56 patients received custom-made neoprene splint
and usual care (intervention) and 53 usual care (control)
Outcome measures: Primary outcome was pain assessed on
Visual Analog Scale (VAS, range 0-100) at 12 month follow-up.
Secondary outcome measures were pain at 1 and 6 month,
disability assessed by the Cochin Hand Function Scale (CHFS,
range 0-90) and pinch strength at 1, 6, and 12 month. Intention-
to-treat analyses were performed.
Results: Pain at 12 month follow-up had signiﬁcantly decreased
in both groups (from 45.5±20.0mm to 23.6±22.8mm in inter-
vention group, p= 0.0001, and from 47.7±20.0 to 39.2±24.2,
p=0.02 in control group), and an inter-group difference was ob-
served (-22.1±25.7 in intervention, and -8.8±25.2 in control
group, p=0.006). Pain inter-group difference was also observed
at 6 month but not at 1 month. Disability at 12 month was
not signiﬁcantly decreased in the intervention group (-2.0±12.9,
p=0.19) but was signiﬁcantly increased in the control group
(3.4±11.3, p=0.04), and an inter-group difference was observed
(p=0.03). Pinch strength was not modiﬁed in intervention and
control group. In the intervention group, 86% of patients wore
their splint at least 5 nights a week at 12 month and no adverse
effect was observed.
Conclusions: Our results suggest that splints are useful, safe,
and acceptable for patients with thumb carpometacarpal joint
OA.
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Purpose: The outcome of the goal study, an independent, long-
term, double-blind RCT in primary care patients with hip os-
teoarthritis (OA), was that glucosamine sulphate (GS) did not
have an effect on the symptoms and progression of hip OA over
the period of two years. In the study protocol subgroup analyses
were pre-speciﬁed to assess the effect of GS in subgroups of
patients.
Methods: In the GOAL study we randomly assigned 222 pa-
tients with hip OA to either 1500 mg of oral GS or a placebo
once daily for two years. Randomisation was stratiﬁed for severity
of radiographic OA (Kellgren and Lawrence (KL) = 1 vs. KL ≥
2) and for localisation (localised vs. generalised OA). For these
groups subgroup analyses were pre-speciﬁed. For additional ex-
ploratory analyses patients were also divided into groups based
on baseline level of pain (VAS ≤ 30 vs. VAS > 30).
General practitioners recruited prevalent hip OA patients. Pa-
tients were eligible when they met at least the clinical set of the
ACR criteria for hip OA. One of the exclusion criteria was being
on the waiting list for a total hip arthroplasty (THA).
Primary outcome measures were Western Ontario MacMas-
ter Universities (WOMAC) pain and function subscales over 24
months (0-100, 0 equals no pain), and joint space narrowing
(JSN) over 24 months. The WOMAC data was analysed using
mixed model analyses incorporating the scores from 3-monthly
questionnaires throughout the study, adjusted for possible con-
founders. The data for JSN was analysed using linear regression
analysis.
Results: We did not ﬁnd a signiﬁcant difference between GS
and placebo in any of the subgroups (Table 1). The outcomes for
WOMAC pain were adjusted for gender and BMI.
Table 1. Results per subgroup
Change from baseline (SD) Adjusted difference
(95% CI)Placebo group GS group
WOMAC pain
KL=1 (n = 117) -1.48 (26.0) -4.73 (19.3) -2.62 (-7.87, 2.63)
KL≥2 (n=105) 3.84 (26.8) 3.61 (21.8) 0.58 (-5.53, 6.69)
WOMAC function
KL=1 -1.04 (18.1) -2.62 (19.0) -3.09 (-7.45, 1.27)
KL≥2 5.58 (21.3) 1.94 (19.3) -0.58 (-6.05, 4.90)
JSN
KL=1 0.007 (0.29) -0.089 (0.36) -0.095 (-0.218, 0.029)
KL≥2 -0.136 (0.35) -0.102 (0.26) 0.066 (-0.082, 0.213)
WOMAC pain
localised (n=85) 1.76 (31.2) -1.10 (20.4) 0.99 (-5.89, 7.88)
generalised (n=137) 0.28 (22.8) -1.76 (21.1) -2.64 (-7.43, 2.14)
WOMAC function
localised 1.17 (23.0) -2.23 (20.2) -1.58 (-7.41, 4.24)
generalised 2.44 (17.3) 0.28 (18.3) -2.18 (-6.47, 2.10)
WOMAC pain
VAS ≤ 30 (n=122) 6.13 (23.7) 1.10 (21.0) -2.68 (-7.44, 2.08
VAS > 30 (n=100) -8.02 (28.5) -4.52 (20.1) -0.54 (-6.86, 5.78)
WOMAC function
VAS ≤ 30 4.81 (20.0) 1.09 (20.3) -3.14 (-7.40, 1.12)
VAS > 30 -3.10 (18.6) -3.13 (17.5) 1.56 (-7.27, 4.16)
In the subgroup of patients with KL = 1, the pain score of patients
on GS was better, while in the group with KL ≥ 2 this score was
better for the patients taking placebo. For WOMAC function the
estimates were in favour of placebo in both subgroups.
For subgroup analyses on the outcome for JSN, we found for
the group with KL = 1 that the patients taking placebo had less
JSN. In the group with KL ≥ 2 the patients in the GS group had
less JSN. None of the differences in the subgroups based on
radiographic severity were statistically signiﬁcant.
When we divided patients on the basis of localisation, we found
that in the group of patients with generalised OA, the patients
on GS scored better on pain and function than the patients
on placebo. Of the patients with localised OA, the ones taking
GS scored better on WOMAC function, while the patients taking
placebo scored better on WOMAC pain. The differences seen in
the subgroups based on localisation of OA were not statistically
signiﬁcant.
Finally we divided patients on the basis of their baseline VAS pain
score. In the group scoring lower than or equal to 30, the patients
taking GS had a better score on the WOMAC pain and function.
For the group with a baseline VAS of over 30, the ones on GS
scored better on WOMAC pain, but worse on WOMAC function.
Again, the differences described in the subgroups based on
baseline VAS score were not statistically signiﬁcant.
Conclusions: A once daily dose of 1500 mg of glucosamine
